Kevzara Fails COVID-19 Patients for the Last Time
Another attempt to repurpose an existing drug into a COVID-19 treatment has failed. In a phase 3 study with 420 severely ill COVID-19 patients, adding an anti-inflammation drug called Kevzara to standard hospital care didn't produce any significant benefits.
Kevzara from the partners Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) is an interleukin 6 (IL-6) inhibitor approved by the FDA to treat rheumatoid arthritis patients. It's almost always a bad idea to suppress an immune system when it's trying to fight COVID-19 or any infection, except in extreme cases when that immune system enters a lethal hyperinflammatory state.
Image source: Getty Images.
Source Fool.com
